This third type of implant is filled with saline, but uses an internal structure to make it behave as if filled with silicone gel. It contains a series of nested shells that support the upper pole when upright and control fluid movement to prevent bouncing. The result is an implant that combines certain key features and benefits from both saline and silicone gel implants. Like the saline implant, the filler is only saline, which women like for peace of mind in case of a rupture/deflation. Like the silicone gel implant, it has a natural feel, but without the risk of silent rupture and FDA-recommended MRIs -women can simply look in the mirror and know their implants are intact. 
METHODS:

RESULTS:
For the 438 patients with 6-year follow-up, patient satisfaction with the outcome was 89.7% for primary and 91.6% for replacement augmentations; surgeon satisfaction with the outcome was 92.6% for primary and 94.0% for replacement augmentations. Adverse events per patient were tabulated by Kaplan-Meier risk rates of first occurrence: Baker class 3 & 4 capsule contracture -5.7% for primary, 11.5% for replacements; rupture/deflation -1.8% for primary, 4.7% for replacements.
CONCLUSION: 6-year results from 438 women show that the structured breast implant has a high rate of patient and surgeon satisfaction, a low rate of capsule contracture and a low rate of rupture/ deflation. Current tissue engineering efforts are aimed towards recreating tissues to repair those that have been lost or damagedsuch as the development of in vitro 3D biomimetic platforms to recapitulate in vivo conditions. Specifically, in breast cancer research, surrounding ECM in vivo has a profound effect on malignant invasion of cancer cells and it has also been clinically observed that breast tumor tissue is denser than normal tissue. However, traditional cell culture systems employed to study tumor cell behavior are limited by the significantly different cell phenotype induced under 2D culture conditions. We have created intact functional vascularized channels in biocompatible collagen constructs with proper in vivovascular physiology and alter collagen stiffness to study factors that influence tumor progression, and vascular remodeling.
Tissue Engineering a Biomimetic Platform for the Study of Breast Cancer Metastasis
METHODS:
Type-I collagen was enzymatically stiffened with ribose solution to create a stock collagen solution. Pluronic F127 fibers, were sacrificed in the collagen, creating a central looped microchannel with a tumor spheroid embedded in the collagen bulk. A cell suspension of human aortic smooth muscle cells (HASMC) and human umbilical vein endothelial cells (HUVEC) was seeded into the microchannel. Mechanical compression testing was completed by ElectroForce-3200 Series III.
RESULTS:
Confocal reflectance values showed no statistical changes of fiber length or pore area in enzymatically altered collagen, suggesting changing the stiffness would not affect bulk cell migration. Biomechanical testing of stiffened collagen revealed that 200mM of ribose dosed collagen increased the stiffness of the hydrogels to appropriate "tumor" stiffness (4kPa). 1 After all time points, non-cancer containing constructs contained microchannels consisting of an anatomically correct robust vascular channel lining with increasing proliferation. However, in cancer constructs, degradation of the vascular lining and aberrantly organized HUVEC and HASMC were present. IHC and MPM imaging revealed the presence of breast cancer cells invading the endoluminal lining. Permeability studies using TexasRed Dextran revealed an increase of neovessel permeability correlating with increasing stiffness, suggesting metastatic potential of cancer also increased.
CONCLUSION:
This model overcomes the limitations of previous 2D and 3D culture models and may be used to investigate any type of tumor cell and can lead to the further understanding of breast cancer signaling pathways, as well as potentially provide an effective platform for high throughput analysis of patient specific breast cancer cells.
